Sox9 regulates alternative splicing and pancreatic beta cell function.
Sapna PuriHasna MaachiGopika NairHolger A RussRichard ChenPamela PulimenoZachary CuttsVasilis NtranosMatthias HebrokPublished in: Nature communications (2024)
Despite significant research, mechanisms underlying the failure of islet beta cells that result in type 2 diabetes (T2D) are still under investigation. Here, we report that Sox9, a transcriptional regulator of pancreas development, also functions in mature beta cells. Our results show that Sox9-depleted rodent beta cells have defective insulin secretion, and aging animals develop glucose intolerance, mimicking the progressive degeneration observed in T2D. Using genome editing in human stem cells, we show that beta cells lacking SOX9 have stunted first-phase insulin secretion. In human and rodent cells, loss of Sox9 disrupts alternative splicing and triggers accumulation of non-functional isoforms of genes with key roles in beta cell function. Sox9 depletion reduces expression of protein-coding splice variants of the serine-rich splicing factor arginine SRSF5, a major splicing enhancer that regulates alternative splicing. Our data highlight the role of SOX9 as a regulator of alternative splicing in mature beta cell function.
Keyphrases
- stem cells
- transcription factor
- induced apoptosis
- cell cycle arrest
- type diabetes
- endothelial cells
- signaling pathway
- cell death
- genome editing
- poor prognosis
- gene expression
- metabolic syndrome
- skeletal muscle
- binding protein
- mesenchymal stem cells
- insulin resistance
- deep learning
- artificial intelligence
- heat shock
- protein kinase
- glycemic control
- genome wide identification
- copy number
- protein protein